ORUKA THERAPEUTICS INC (ORKA)
Health Care · Monoclonal antibody therapeutics for inflammatory and immunology indications · NASDAQ
Clinical-stage biopharmaceutical company developing novel monoclonal antibodies with extended half-life for inflammatory and immunology indications, led by IL-23p19 and IL-17A/F targeted programs for psoriasis and related conditions.
What ORUKA THERAPEUTICS INC does
Oruka Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis and other inflammatory and immunology indications. The company applies antibody engineering and format innovations to validated modes of action, incorporating half-life extension technology to improve efficacy and reduce dosing frequency. Its lead program, ORKA-001, targets the p19 subunit of interleukin-23 (IL-23p19) for psoriasis treatment, while co-lead program ORKA-002 targets interleukin-17A/F for psoriasis, hidradenitis suppurativa, psoriatic arthritis, and other conditions. The company has not yet generated any product revenue and is currently in Phase 1/2a clinical development stages.
Themes: ["Monoclonal antibody therapeutics","Psoriasis / dermatology","IL-23 inhibition","IL-17 inhibition","Inflammatory and immunology (I&I)","Half-life extension technology","Disease-modifying therapy"]
Fundamentals
- Price$88.27 as of 2026-07-09 close
- Market cap$5.2B as of 2026-07-10
- 1-year return+520.3% as of 2026-07-09 close
- Net margin-26.3% as of 2026-07-10
- ROE-26.0% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Beta-0.38 as of 2026-07-10
Key risks (from latest filing)
[]
Competitors & peers
- Eli Lilly (LLY) - IL-23p19 inhibitor (tirzepatide/GLP-1 class); IL-17 programs
- AbbVie (ABBV) - risankizumab (IL-23p19) for psoriasis
- Novartis (NVS) - IL-17 inhibitors and psoriasis therapeutics
- Regeneron (REGN) - monoclonal antibody platform, inflammatory disease programs
- Janssen Pharmaceuticals (J&J) - IL-23 and IL-17 inhibitors for psoriasis/autoimmune
- Amgen (AMGN) - IL-17 inhibitors and inflammatory disease programs
- Boehringer Ingelheim - inflammatory and immunology therapeutics
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.